Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2012 - 2018)
Catalyst Pharmaceuticals (CPRX) posted Current Deferred Revenue of $33408.0 for Q4 2018, up 52.45% on a QoQ basis from $21914.0 in Q3 2018, and up 39.14% year-over-year from $24011.0 in Q4 2017.
Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2012 - 2018) Analysis & Trends
Catalyst Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $33408.0 for Q4 2018.
- Quarterly Current Deferred Revenue rose 39.14% year-over-year to $33408.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $33408.0 (up 39.14% YoY) and the FY2018 annual result came in at $33408.0, up 39.14% from the prior year.
- Current Deferred Revenue was $33408.0 for Q4 2018 at Catalyst Pharmaceuticals, up from $21914.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $33408.0 in Q4 2018 and bottomed at $3254.0 in Q1 2014.
- A 5-year average of $16181.7 and a median of $18094.0 in 2016 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2015 — Current Deferred Revenue soared 335.14% — and 2018, when it declined 2.27%.
- Catalyst Pharmaceuticals' Current Deferred Revenue stood at $4158.0 in 2014, then surged by 335.14% to $18093.0 in 2015, then rose by 0.01% to $18094.0 in 2016, then jumped by 32.7% to $24011.0 in 2017, then soared by 39.14% to $33408.0 in 2018.
- Business Quant data shows CPRX's Current Deferred Revenue at $33408.0 in Q4 2018, $21914.0 in Q3 2018, and $27184.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 33,408.00 |
| Sep 30, 2018 | 21,914.00 |
| Jun 30, 2018 | 27,184.00 |
| Mar 31, 2018 | 25,597.00 |
| Dec 31, 2017 | 24,011.00 |
| Sep 30, 2017 | 22,424.00 |
| Jun 30, 2017 | 20,867.00 |
| Mar 31, 2017 | 19,328.00 |
| Dec 31, 2016 | 18,094.00 |
| Dec 31, 2015 | 18,093.00 |
| Sep 30, 2015 | 18,093.00 |
| Jun 30, 2015 | 5,702.00 |
| Mar 31, 2015 | 4,930.00 |
| Dec 31, 2014 | 4,158.00 |
| Sep 30, 2014 | 4,270.00 |
| Jun 30, 2014 | 3,762.00 |
| Mar 31, 2014 | 3,254.00 |
| Dec 31, 2013 | 2,746.00 |
| Sep 30, 2013 | 2,245.00 |
| Jun 30, 2013 | 1,752.00 |